During this episode, Lumanity experts Rob Rawlinson and Kate Goacher discuss insights and takeaways from their recent attendance at the 2024 European Society for Medical Oncology (ESMO) conference. Their conversation covers a variety of topics, including:

• The importance of the patient and including the patient voice in drug development
• The way that Artificial Intelligence (AI) could impact and innovate cancer care
• Insights on a selection of early-phase extensive-stage small-cell lung cancer (ES-SCLC) assets